Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Arovella Therapeutics Limited (AU:ALA)
ASX:ALA
Holding AU:ALA?
Track your performance easily
ALA Stock Chart & Stats
Day’s RangeAU$0 - AU$0
52-Week RangeAU$0.06 - AU$0.19
Previous CloseAU$0.14
Volume431.54K
Average Volume (3M)1.21M
Market Cap
AU$152.51M
Enterprise ValueAU$146.58M
Total Cash (Recent Filing)AU$6.07M
Total Debt (Recent Filing)AU$144.80K
Price to Earnings (P/E)―
Beta0.69
Next Earnings
Feb 26, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares OutstandingN/A
10 Day Avg. Volume831,378
30 Day Avg. Volume1,209,196
Standard Deviation0.20
R-Squared0.00564
Alpha0.02
Financial Highlights & Ratios
Price to Book (P/B)N/A
Price to Sales (P/S)76.03
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Arovella Therapeutics Limited News
PremiumCompany Announcements
Arovella Therapeutics Emphasizes Strong Governance
PremiumCompany Announcements
Arovella Therapeutics Affirms Strong Governance
PremiumCompany Announcements
Arovella Therapeutics Posts Lower Annual Loss
PremiumCompany Announcements
Arovella’s ALA-101 Gains FDA Nod Towards Trials
PremiumCompany Announcements
Arovella Therapeutics Advances Cancer Cell TherapyPremiumCompany Announcements
Arovella Therapeutics Expands Share CapitalPremiumCompany Announcements
Arovella Therapeutics Expands Share Quotation
PremiumCompany Announcements
Arovella Therapeutics Showcases Cancer BreakthroughsOptions Prices
Currently, No data available
---
Ownership Overview
6.51% Insiders
0.00% Mutual Funds
0.00% Other Institutional Investors
93.49% Public Companies and
Individual Investors
ALA FAQ
What was Arovella Therapeutics Limited’s price range in the past 12 months?
Arovella Therapeutics Limited lowest share price was AU$0.06 and its highest was AU$0.18 in the past 12 months.
What is Arovella Therapeutics Limited’s market cap?
Currently, no data Available
When is Arovella Therapeutics Limited’s upcoming earnings report date?
Arovella Therapeutics Limited’s upcoming earnings report date is Feb 26, 2025 which is in 171 days.
How were Arovella Therapeutics Limited’s earnings last quarter?
Arovella Therapeutics Limited released its earnings results on Aug 21, 2024. The company reported -AU$0.005 earnings per share for the quarter, missing the consensus estimate of N/A by -AU$0.005.
Is Arovella Therapeutics Limited overvalued?
According to Wall Street analysts Arovella Therapeutics Limited’s price is currently Overvalued.
Does Arovella Therapeutics Limited pay dividends?
Arovella Therapeutics Limited does not currently pay dividends.
What is Arovella Therapeutics Limited’s EPS estimate?
Arovella Therapeutics Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Arovella Therapeutics Limited have?
Arovella Therapeutics Limited has 1,051,775,600 shares outstanding.
What happened to Arovella Therapeutics Limited’s price movement after its last earnings report?
Arovella Therapeutics Limited reported an EPS of -AU$0.005 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -6.667%.
Which hedge fund is a major shareholder of Arovella Therapeutics Limited?
Currently, no hedge funds are holding shares in AU:ALA
---
Arovella Therapeutics Limited Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
108.95%
12-Months-Change
Fundamentals
Return on Equity
-116.55%
Trailing 12-Months
Asset Growth
142.82%
Trailing 12-Months
Company Description
Arovella Therapeutics Limited
Arovella Therapeutics Ltd is a biotechnology company focused on developing therapies to treat human diseases. Its two focus areas are oncology and conditions that impact the central nervous system.
---
Technical Analysis
---